Real-world data shows that rituximab is more effective than cladribine

During 2017-2019, systematic differences in high efficacy MS-treatment strategies were preferred in Oslo (cladribine) and Bergen (rituximab). Comparisons of long-term (median 4.5 years) effects from these different treatments showed a 2.7 higher risk for new MRI disease activity after four years in the cladribine group (n=132) compared to rituximab group (n=168). Patients receiving cladribine also had a higher risk of relapses and disability worsening, our results suggest that rituximab should be preferred over cladribine as therapy for most patients with MS. See abstract from the annual meeting for the Norwegian Neurological association here.